Fig. 7From: Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patientsMetabolic network analysis enables pancreatic adenocarcinoma (PA) prognostication. Long-term survival-related samples (n = 8) were compared to short-term survival samples (n = 9) according to ADEMA results. No neoadjuvant chemotherapy was used. The red, green, and blue arrows, respectively, indicate the metabolites that are predicted to increase, decrease, or remain stable in long-term survivorsBack to article page